ChemoCentryx, Inc. (CCXI) financial statements (2020 and earlier)

Company profile

Business Address 850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1711771271187173133
Cash and cash equivalents36284012131610
Short-term investments135149871065857123
Receivables 25130   
Other undisclosed current assets2211111
Total current assets:1731811801497274134
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment2211111
Long-term investments and receivables35 8654117
Long-term investments35 8654117
Other noncurrent assets1000000
Total noncurrent assets:4029764318
TOTAL ASSETS:21218318915678117152
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19141095107
Accounts payable1111111
Accrued liabilities181399576
Employee-related liabilities     2 
Deferred revenue37
Debt      0
Deferred revenue and credits2329   
Other undisclosed current liabilities 50   (2) 
Total current liabilities:55643338587
Noncurrent Liabilities
Long-term debt and lease obligation, including:20205   0
Long-term debt, excluding current maturities2020    0
Other undisclosed long-term debt and lease obligation  5    
Liabilities, other than long-term debt7507268000
Deferred revenue and credits7268   
Deferred revenue74
Other liabilities1000000
Other undisclosed noncurrent liabilities 84     
Total noncurrent liabilities:951047768000
Total liabilities:150169110106687
Stockholders' equity
Stockholders' equity attributable to parent, including:6215795073109145
Common stock0000000
Additional paid in capital476389369357340328318
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0)0
Accumulated deficit(414)(374)(289)(307)(267)(220)(173)
Stockholders' equity note, subscriptions receivable(0)(0)(0)(0)
Other undisclosed stockholders' equity attributable to parent    (0)(0)(0)
Total stockholders' equity:6215795073109145
TOTAL LIABILITIES AND EQUITY:21218318915678117152

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net8212  6
Revenue from related parties2643
Gross profit:35438212  6
Operating expenses(89)(83)(66)(53)(48)(47)(45)
Operating income (loss):(54)(40)16(41)(48)(47)(39)
Nonoperating income3211000
Investment income, nonoperating5411001
Interest and debt expense(2)(1)(0)  (0)(0)
Income (loss) before gain (loss) on sale of properties:(53)(39)18(40)(47)(47)(39)
Other undisclosed net income11     
Net income (loss):(52)(38)18(40)(47)(47)(39)
Other undisclosed net income attributable to parent1 0  00
Net income (loss) available to common stockholders, diluted:(51)(38)18(40)(47)(47)(39)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(52)(38)18(40)(47)(47)(39)
Comprehensive income (loss):(52)(38)18(40)(47)(47)(39)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent2(0)(0)(0)0(0)0
Comprehensive income (loss), net of tax, attributable to parent:(50)(38)18(40)(47)(47)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: